Core One In Talks With Multiple Companies To Supply Psilocybin
Core One In Talks With Multiple Companies To Supply Psilocybin
Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6), (WKN:A3CSSU) announced that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient psilocybin to meet their psychedelic research needs.
Core One Labs Inc(OTCQB: CLABF) (CSE: COOL) (法蘭克福:LD6)，（WKN: A3CSSU）宣佈它 正在與多個藥物實驗室和研究組織討論向他們提供活性藥物成分 psilocybin 以滿足他們的迷幻研究需求。
Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer's and Parkinson's diseases, to name a few. Promising results from many of these trials, though still in early stages and requiring further study, have given rise to rapid growth of a psychedelic industry and the emergence of many public and private entities engaged in research with psychedelics intended for medical use.
近年來，科學界對psilocybin的興趣呈指數級增長，許多備受矚目的臨床試驗表明，這種迷幻化合物在治療各種心理健康和神經系統疾病方面具有巨大的潛力，例如焦慮、抑鬱、強迫症、各種成癮以及阿爾茨海默氏症和帕金森氏病等。其中許多試驗的結果令人鼓舞，儘管仍處於初期階段，需要進一步研究，但促成了迷幻行業的快速發展，並出現了許多公共和私人實體從事用於醫療用途的迷幻藥的研究。
The company has the potential to produce its own psychedelic compounds at a Good Manufacturing Practices facility, while, in collaboration with its partners, also manufactures and could supply its quality and cost-effective products to licensed clients in Canada.
該公司有可能在Good Manufacturing Practions工廠生產自己的迷幻化合物，同時還與其合作伙伴合作，生產高質量且具有成本效益的產品，並可能向加拿大的持牌客戶提供其優質且具有成本效益的產品。
By streamlining a psychedelic supply chain and structuring itself as a vertically integrated business, Core One could control the production process of its products and develop an uninterrupted revenue stream. Management regards a robust and reliable supply chain as a key component in establishing its business clientele and capturing a large share of the medicinal and clinical psychedelics' market.
通過精簡迷幻的供應鏈並將自己構建爲垂直整合的業務，Core One可以控制其產品的生產過程並開發不間斷的收入來源。管理層認爲，強大而可靠的供應鏈是建立業務客戶羣和佔據藥物和臨床迷幻藥市場很大份額的關鍵組成部分。
"Engaging in talks with multiple companies to supply them with psychedelic compounds demonstrates how far the company has come since initial research and development stages to where it is now. Embarking on the sales aspect of our corporate strategy keeps us ahead of the pack when it comes to being a leading supplier of medicinal psychedelics. We believe that our ability to continue to execute on our goals demonstrates to shareholders and other pharmaceutical companies why Core One is positioned to disrupt the medical industry when it comes to mental health and addiction treatments," stated Joel Shacker, Core One Labs CEO.
“與多家公司進行談判，爲他們提供迷幻化合物，這表明該公司自最初的研發階段以來已經走了多遠。在成爲藥用迷幻藥的領先供應商方面，我們開始進入公司戰略的銷售方面使我們處於領先地位。我們相信，我們繼續實現目標的能力向股東和其他製藥公司表明，爲甚麼Core One有能力在心理健康和成癮治療方面顛覆醫療行業，” 他說 Joel Shacker，Core One Labs 首席執行官
Photo: Benzinga edit with photos by geralt, sergeitokmakov on Pixabay
照片：Benzinga 在 Pixabay 上用 geralt、sergeitokmakov 的照片進行編輯
Related News
相關新聞
Core One's Awakened Lays The Groundwork For The Large-Scale Production Of Psychedelic Compounds With Synthetic Production Of Psilocin
Core One's Awakened 爲大規模生產迷幻化合物和合成生產賽洛辛奠定了基礎